Oxytocin clinical trials
Oxytocin is named as an intervention in 20 current clinical trials in our China, Canada, Switzerland, Germany, France, Sweden, Denmark and Israel registers. 18 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is University of Electronic Science and Technology of China (5). The most-studied condition is Postpartum Hemorrhage. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Where Oxytocin is approved
All regulators →Of the three regulators tracked here, the first to approve Oxytocin was the US, on 17 Apr 1980.
- 1 EU orphan designation, most recently for treatment of Prader-Willi syndrome (29 Jul 2014, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Oxytocin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Oxytocin works
All drug targets →- Oxytocin receptor agonist AgonistTarget: OXTR oxytocin receptor✓ In ChEMBL and the Guide to Pharmacology
- InfertilityPhase 3
- Neonatal sepsisPhase 3
- Prader-Willi syndromePhase 3
- Premature rupture of membranesPhase 3
- TinnitusPhase 3
- Alcohol dependencePhase 3
- Alcohol withdrawalPhase 3
- AutismPhase 3
- Cesarean sectionPhase 3
- DystociaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL395429, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2176, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Oxytocin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 5 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Oxytocin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Oxytocin
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Oxytocin in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Oxytocin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Assessment of self-perceived stress and repetitive behaviors after six weeks of daily intranasal oxytocin administration versus placebo: a randomised, multicentre, parallel group pragmatic trial in 210 men and women with autism
2025-524797-42-00 · CTIS ↗ · Mental Disorders
|
Phase 3 | Authorised | UZ Leuven | Belgium |
|
Leveraging the neural mechanisms of social reward for drug relapse prevention
2023-504518-31-01 · CTIS ↗ · Mental Disorders
|
Phase 2 | Authorised | Fondazione Santa Lucia IRCCS | Italy |
Oxytocin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
5 single-substance products containing Oxytocin on the HPRA medicines list.
- Ofost 10 IU/ml concentrate for solution for infusion or solution for intramuscular injectionAS Grindeks · PA22992/001/002 · Marketed
- Ofost 5 IU/ml concentrate for solution for infusion or solution for intramuscular injectionAS Grindeks · PA22992/001/001 · Marketed
- Syntocinon Ampoules 10 IU/ml solution for injection/infusionAlfasigma S.p.A · PA2206/003/002 · Marketed
- Syntocinon Ampoules 5 IU/ml solution for injection/infusionAlfasigma S.p.A · PA2206/003/001 · Marketed
- Oxytocin 10 IU/ml Concentrate for Solution for InfusionPinewood Laboratories Ltd · PA0281/239/001 · Not marketed
Supply shortages
- Oxytocin 5 I.E. HexalGermany (BfArM) · Other reason · 8 Jun 2026 to 11 Nov 2026
Conditions studied with Oxytocin
22 conditionsAll 22 conditions
| Condition (as registered) | Trials |
|---|---|
| Postpartum Hemorrhage | 4 |
| Healhty | 2 |
| Arginine Vasopressin Deficiency | 2 |
| Healthy Adult Male | 1 |
| Healthy | 1 |
| Healthy Adult Participants | 1 |
| Schizophrenia Spectrum Disorders (SSD) | 1 |
| Cervical Ripening | 1 |
| Unfavorable Cervix | 1 |
| Autism Spectrum Disorder | 1 |
| Acute Pain | 1 |
| Glucose Metabolism Disorders (Including Diabetes Mellitus) | 1 |
| Depressive Symptoms | 1 |
| Human-Animal Interaction | 1 |
| Central Diabetes Insipidus | 1 |
| Oxytocin Deficiency | 1 |
| Diabetes Insipidus | 1 |
| Postpartum Hemorrhage (Primary) | 1 |
| Post Partum Hemorrhage | 1 |
| Twin Pregnancy | 1 |
| Menstrual Cycle | 1 |
| Hormonal Contraception | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Oxytocin trials
How many clinical trials are testing Oxytocin?
20 current trials in our China, Canada, Switzerland, Germany, France, Sweden, Denmark and Israel registers name Oxytocin as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Oxytocin trials recruiting patients?
Yes. 18 of the 20 trials are recruiting: 5 with sites in China, 5 with sites in Canada, 3 with sites in Switzerland, 1 with sites in Germany, 1 with sites in France, 1 with sites in Sweden, 1 with sites in Denmark and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Oxytocin clinical trials?
University of Electronic Science and Technology of China (5), Samuel Lunenfeld Research Institute, Mount Sinai Hospital (5), University Hospital, Basel, Switzerland (2) and Central Institute of Mental Health, Mannheim (1), among 11 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Oxytocin licensed in Ireland?
Yes. The HPRA medicines list includes 5 single-substance products containing Oxytocin, for example Ofost 10 IU/ml concentrate for solution for infusion or solution for intramuscular injection (AS Grindeks). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Oxytocin shortage?
The registers we track list 1 entry for Oxytocin: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Oxytocin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Oxytocin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Oxytocin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.